TDM1

Phase 2Small molecule

IInstitut du Cancer de Montpellier - Val d'Aurelle

TDM1 is one of 23 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

TDM1

IInstitut du Cancer de Montpellier - Val d'Aurelle

Phase 2

2 10

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Not yet recruiting

Breast Cancer

NCT04301375

Clinical

Trials by Indication[1]

Breast Cancer2 trials

Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial)

Not yet recruiting·DDavid Garcia Cinca·Phase 2·NCT04301375·27 enrolled

Patients With Brain Metastases From HER2-positive Breast Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1·NCT02135159·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for TDM1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — TDM1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for TDM1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut du Cancer de Montpellier - Val d'Aurelle company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: IInstitut du Cancer de Montpellier - Val d'Aurelle

TDM1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Breast Cancer2 trials

References

Drug Info

Quick Facts

Related News